Table 3. Univariate analyses of PFS and OS between clinical characteristics (n = 66).
| Characteristics | PFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Gender | 0.76–2.07 | 0.62–1.82 | 0.815 | |||
| Male | 1.00 | 0.383 | 1.00 | |||
| Female | 1.25 | 1.07 | ||||
| Smoking status | 0.35–1.38 | 0.303 | 0.47–2.12 | 0.983 | ||
| Never smoker | 1.00 | 1.00 | ||||
| Smoker | 0.70 | 0.99 | ||||
| Age | 1.00 | 0.98–1.02 | 0.882 | 1.00 | 0.98–1.02 | 0.761 |
| TKI-free interval | 0.24–0.98 | 0.044 | 0.58–2.67 | 0.561 | ||
| < 3 m | 1.00 | 1.00 | ||||
| ≥ 3 m | 0.48 | 1.25 | ||||
| ECOG PS | 0.36–1.03 | 0.064 | 0.19–0.61 | < 0.001 | ||
| 0~1 | 1.00 | 1.00 | ||||
| ≥ 2 | 0.61 | 0.34 | ||||
| EGFR type | 0.49–1.36 | 0.442 | 0.44–1.28 | 0.292 | ||
| Exon 19 deletion | 1.00 | 1.00 | ||||
| Exon 21 L858R mutation | 0.82 | 0.75 | ||||
| Initial PFS | 0.37–1.25 | 0.213 | 0.35–1.28 | 0.222 | ||
| < 6 m | 1.00 | 1.00 | ||||
| ≥ 6 m | 0.68 | 0.67 | ||||
| Insertion chemotherapy | 0.34–1.09 | 0.092 | 0.57–1.97 | 0.853 | ||
| None | 1.00 | 1.00 | ||||
| Cytotoxic agent | 0.60 | 1.06 | ||||
PFS, progression-free survival. OS, overall survival. PS, performance status; HR, hazard ratio. CI, confidence interval.